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Abstract
Background: Neopterin, a product of  cell-mediated immunity, is a non-specific biomarker of  inflammation. Plasma/serum is 
generally the body fluid of  choice for neopterin assessment, but urine is often used as it does away with venepuncture.  Analysis 
of  urine neopterin is based on collection of  a single urine sample and expressed as μmol neopterin/mol creatinine.
Objectives: To examine published correlations between plasma neopterin levels and urine neopterin:creatinine ratios and to 
determine whether they are in diagnostic agreement. 
Methods: Literature search was performed by databases and by hand. Databases included Academic Search Complete; Afri-
ca-Wide Information; AHFS Consumer Medication Information; eBook Collection (EBSCOhost); Family & Society Studies 
Worldwide; MasterFILE Premier; MEDLINE; TOC Premier.
Results: Positive correlations of  varying statistical significance generally exist between plasma neopterin and urine neopter-
in:creatinine ratios. With a decline in renal clearance, plasma neopterin over-estimates inflammatory activity. With immune-com-
plex renal disease, urine neopterin:creatinine ratios  over-estimate systemic inflammation. The two biomarkers can differ in 
diagnostic validity.
Conclusion: Correlations between plasma neopterin and urine neopterin:creatinine ratios suggest both as suitable biomarkers. 
However, since correlations reflect equality of  means and not individual values, significant correlations, do not necessarily imply 
diagnostic agreement. Therefore, plasma and urine cannot summarily be assumed interchangeable for diagnostic/prognostic 
purposes.
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Introduction
Inflammatory mediators are involved in virtually all nor-
mal physiological and psychological/mental processes in 
the body1.  In addition to their role in the regulation of  
peripheral immune, cardiovascular, metabolic and other 
activities, they are essential for normal central nervous 
system processes such as synaptic plasticity, neurogene-
sis and neuromodulation2.  On the downside, excessive 
inflammatory activity has been reported in association 
with a host of  physical disorders, not only infectious and 
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License (https://creativecommons.org/licenses/BY/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the 
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inflammatory conditions, but also metabolic-, cardiovas-
cular-, skeletal- and nutrition-related disturbances not 
primarily associated with inflammatory processes3,4. Like-
wise for psychiatric and cognitive disorders, where abnor-
mal inflammatory status is known to occur in a wide va-
riety of  psychiatric syndromes3,5 and to have detrimental 
effects on memory, neural plasticity and neurogenesis2,6. 
In fact, inflammation has been shown to be a common 
denominator in more physical and neuropsychiatric dis-
orders than ever before anticipated3,5,7. 
In view of  the central role of  inflammatory process-
es in health and disease, a variety of  specific, as well as 
non-specific, inflammatory biomarkers are measured in 
research and in clinical medicine, in an attempt to esti-
mate a patient’s inflammatory status, as well as to monitor 
disease progression or the effects of  therapeutic inter-
ventions.  Neopterin, a product of  cell-mediated immuni-
ty, is probably, among the non-specific biomarkers most 
often employed as an inflammatory biomarker8.
Neopterin has been shown, both in our laboratory and 
in that of  others,8 to be a good non-specific indicator 
of  pro-inflammatory activity and a useful biomarker in 
numerous infectious and non-infectious disorders, in-
cluding many not previously associated with cellular im-
mune activity.  As such it is commonly used to estimate 
inflammatory status and prognosis, as well as to monitor 
the progression of  disease, the effects of  therapeutic in-
terventions, and to estimate exposure to toxic industrial 
substances8-13.
Plasma or serum is generally the body fluid of  choice for 
the assessment of  neopterin levels10,11.  However, a multi-
tude of  studies exist where urine neopterin levels, rather 
than plasma levels, have been determined as biomarkers10. 
Analysis of  urine neopterin is, in the majority of  cases, 
based on the collection of  a single urine sample and ex-
pressed as μmol neopterin/mol creatinine.  Although the 
handling of  urine from infectious patients may carry a 
smaller risk than plasma11, the reason, in the majority of  
studies, for using urine rather than plasma is that it does 
away with the need for venepuncture.
Both plasma and urine neopterin increase with increas-
es in cell-mediated immunity.  Authorities in the field, as 
early as 1992, already claimed that neopterin concentra-
tions in serum and in urine increase in parallel to the clin-
ical course of  infections and are significant predictors of  
disease progression11. Whether such a linear relationship 
between plasma neopterin levels and the urine neopter-
in:creatinine ratio does indeed invariable exist and, per-
haps more importantly, whether these two markers ex-
hibit diagnostic agreement, is of  practical interest.  This 
paper examines published correlations between plasma 
neopterin levels and the urine neopterin:creatinine ratio 
and addresses the question of  whether diagnostic agree-
ment exists between the two,  i.e., whether they can be 
considered interchangeable for diagnostic or prognostic 
purposes.
Methods
Literature searches were performed by databases and by 
hand.  Databases used included Academic Search Com-
plete; Africa-Wide Information; AHFS Consumer Med-
ication Information; eBook Collection (EBSCOhost); 
E-Journals; Family & Society Studies Worldwide; Health 
Source: Consumer Edition; Health Source: Nursing/Ac-
ademic Edition; MasterFILE Premier; MEDLINE; TOC 
Premier.
Results
Most studies assessed neopterin in either plasma/serum 
or in urine. Nevertheless, a fair number of  studies could 
be found where neopterin was measured in plasma or se-
rum, as well as in urine. Unfortunately, about two thirds 
of  them did not report correlations. Studies that did re-
port on the correlations between serum/plasma levels 
and the urine neopterin:creatinine ratio are summarized 
in Table 1. Correlations varied from non-significant to 
highly significant, with the majority showing some sort of  
statistically significant correlation between the two. The 
diagnostic agreement/non-agreement between the re-
sults of  each study is given in the fifth column of  Table 1.
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Patients Plasma/serum neopterin 
(nmol/L)
Urine neopterin 
(μmol/mol creatinine)
Correlation co-efficient;        
(p-value)
Diagnostic 
agreement/non-
agreement
Reference
Patients with rectal 
carcinoma undergoing 
chemoradiation (n=49)  
Week 1 (n=49)    
Week 2 (n=46)
Week 3 (n=44)
Week 4 (n=44)
Week 5 (n=43)
Week 6 (n=42)
Week 7 (n=36)
No controls
11.1±13.0 
13.3±17.2
9.7±5.6
9.5±4.7
11.2±6.5
10.7±5.4
12.3±9.5
measured by 
radioimmunoassay (RIA)
197±102
254±201
243±188
213±106
248±148
251±144 
313±281
measured by high 
performance liquid
chromatography (HPLC)
rs=0.707; (< 0.000001)
rs=0.557; (0.0001)
rs=0.552; (0.0001)
rs=0.770; ( < 0.000001)
rs=0.439; (0.003)
rs=0.466; (0.002)
rs=0.589; (0.0002)
Only the urine 
neopterin:creatinine ratios 
were associated with the 
irradiated gut volume.  
Serum 
neopterin:creatinine ratio 
correlated with the 
toxicity of the therapy 
more closely than the 
absolute serum neopterin 
concentrations.
[24] 
Zinc-exposed 
galvanization workers 
(n=63)
Controls (n=23)
9.55±0.49
5.55±0.54
measured by enzyme-
linked
immunosorbent assay 
(ELISA)
168±6.65
141±5.95
measured by HPLC
rs=0.265; (0.037) for 
entire group
Urine neopterin:creatinine 
ratios and not plasma 
neopterin correlated with 
serum zinc levels.
[25]
Patients with HIV on anti-
retroviral therapy (ART) 
(n=112)
• Before ART
• 12 months on ART
No controls
19.6 (12.1-30.0)
7.3 (4.7-10.6)
measured by ELISA
554 (414-859)
231 (157-309)
measured by HPLC
rs only given for changes 
(∆).
Both plasma and urine 
neopterin were 
significantly raised before 
ART. Following ART Δ 
urine neopterin:creatinine 
correlated with Δ plasma 
neopterin
rs=0.758; (<0.001)
[26]
Patients on haemodialysis  
Controls 
38±0.5 (n=71)
11±1 (n=21)
measured by ELISA
381±29 (n=37)
122±16 (n=20)  
measured by HPLC
r=0.286 (0.148)
rs=0.784; (<0.001)
Duration (yrs) on 
haemodialysis 
significantly influenced 
urinary 
neopterin:creatinine ratio,
but not plasma neopterin 
levels
[27] 
Patients with Behcet’s
disease (n=45)
Controls (n=45)
12.68± 4.87  
6.03± 3.46  
measured by ELISA
167.53 ± 148.73 
104.15 ± 47.74
measured by ELISA
r=0.42; (<0.001) 
r=0.38; (0.008) 
Moderate negative 
correlation between 
serum neopterin and IFN-
γ levels, however no 
correlation between urine 
neopterin:creatinine ratio 
and serum IFN-γ levels.
[28] 
Patients with coal 
workers' pneumoconiosis 
(CWP):
• Simple 
pneumoconiosis 
(n=23)
• Progressive massive 
fibrosis (n=8)
Controls (n=26)
10.72 ±0.98  
14.08 ±3.86 
5.30 ± 0.47 
measured by ELISA
235.17 ±7.40
256.05 ±9.43
140.00 ±5.43
measured by ELISA
For all participants:
r=0.525, (<0.01)
Patient serum neopterin 
levels in CWP were 
higher than controls, 
while urine 
neopterin:creatinine 
levels were within the 
normal range.  
[17]
Patients with tuberculous 
pleurisy (n=34)
Patients with non-
tuberculous pleural 
effusion (n=29)
No controls
38.28± 14.18
22.57±6.02 
measured by HPLC
759.15±622.74
343.10±233.65 
measured by HPLC
r=0.73; (<0.001)
Not reported
Serum neopterin showed 
a diagnostic sensitivity of 
56%, while the diagnostic 
sensitivity of the urine 
neopterin:creatinine ratio 
was only 26%.
[29]
Patients with pulmonary 
tuberculosis (n=38)
Patients with bronchial 
carcinoma (n=13)
Patients with pneumonia 
(n=20)
Healthy volunteers (n=24)
20.6±12.1
14.4±3.7
10.7±3.7
6.2±1.7
measured by RIA
718.5±594.4
331.7±125.6
225.6±69.6
141.8±36.9
measured by HPLC
r=0.81; (<0.001)
r=0.70; (<0.011)
r=0.72; (0.001)
r=0.90; (<0.001)
The increase of neopterin 
above normal was 
markedly higher for urine 
than for serum.  A 
positive correlation was 
found between the 
radiological extent of the 
disease and the urine 
neopterin:creatinine ratio, 
but not between the 
radiological extent of the 
disease and serum 
neopterin values.
[30] 
Patients with juvenile 
idiopathic inflammatory 
myopathies 
Controls 
3.8 (n=13)
1.5 (n=35)
measured by ELISA
5.1 µmol/L (n=45)
1.7 µmol/L (n=79)
measured by HPLC
No significant 
correlations
Urine neopterin correlated 
significantly with various 
clinical measures of 
myositis disease activity, 
while plasma neopterin 
did not correlate with 
these same myositis 
disease activity measures.  
[18]
Renal allograft recipients 
(n=30)
No controls
Not reported 
measured by RIA
Not reported
measured by HPLC
r=0.269 (0.190 to 0.345);   
p-value not reported 
Relating serum neopterin 
to serum creatinine 
improved correlation to 
r=0.779 (0.750-0.805)           
Serum neopterin is not an 
adequate biomarker in 
renal disease, and should 
be expressed relative to 
serum creatinine (as for 
urine).
[15]
Patients with 
gynaecological tumours 
(n=72)
Patients with 
gynaecological tumours 
(n=19)
Healthy
drug-abusers (n=35)
Patient values presented 
only as scatter plots
measured by RIA
Patient values presented 
only as scatter plots
measured by HPLC
rs=0.60 (<0.001)
rs=0.40
rs=0.72 
The discriminatory power 
of the urine 
neopterin:creatinine ratio 
was superior to that of 
serum neopterin (chi 
square: 28.87 vs 17.38).
[16]
Table 1: Correlations and diagnostic agreement between plasma neopterin levels and 
the urine neopterin: creatinine ratio
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Discussion
As seen in Table 1, correlations between serum/plasma 
levels and the urine neopterin:creatinine ratio varied from 
non-significant to highly significant, with the majority 
showing a statistically significant correlation.  As correla-
tion coefficients indicate a linear relationship between 
two numerical measurements, it would suggest both plas-
ma neopterin and the neopterin:creatinine ratio in urine 
to be markers of  pro-inflammatory status, and suitable 
for the serial monitoring of  disease progression or the 
effect of  therapeutic interventions.  This has been sug-
gested by a number of  studies and would, in general, be 
applicable.  Some of  the correlations were, however, only 
weakly significant and in a small number of  studies not 
statistically significant at all.
Possible explanations for variations in the linear re-
lationship between plasma neopterin and the urine 
neopterin:creatinine ratio
In order to better understand the relationship between 
plasma neopterin and the urine neopterin:creatinine ratio, 
and thus the potential for variation in their correlation, it 
is necessary to examine the balance between neopterin 
input to, and removal from the circulation.  
Neopterin is synthesised and released into the circulation 
mainly by macrophages/monocytes and microglial cells 
upon stimulation by interferon-γ9.  It is said to be excret-
ed mainly through the kidneys in an unchanged form9. 
Glomerular filtration is believed to be the primary mech-
anism for the renal clearance of  neopterin and at least 
two studies have found a significant inverse correlation 
between serum neopterin and the creatinine-based esti-
mation of  glomerular filtration rate (GFR)14.  In addition, 
a number of  studies have shown significant positive cor-
relations between the clearance of  neopterin and that of  
creatinine, both in healthy control subjects and in patients 
with renal disease15,16.  Serum neopterin has furthermore 
been shown to correlate with serum creatinine levels in 
patients with a decline in kidney function14. It is therefore 
obvious that plasma/serum neopterin levels would rise 
with a progression in renal dysfunction, irrespective of  
whether cell-mediated immunity increases or not.  That 
could explain the lack of  correlations between plasma/
serum neopterin levels and the urine neopterin:creatinine 
ratio in patients with renal dysfunction and may also ex-
plain the results where the urine neopterin:creatinine ratio 
was superior to plasma as a biomarker16,17,18.  In line with 
this, some laboratories express plasma neopterin levels 
relative to the plasma concentration of  creatinine (μmol 
neopterin in plasma/mol creatinine in plasma) in individ-
uals diagnosed with compromised renal function, thus 
adjusting for renal dysfunction.   This practice could also 
help to distinguish between raised neopterin levels due 
to cellular immune activation and that due to renal insuf-
ficiency15.  It is, however, not routinely done and would 
probably not be an issue in patients with normal renal 
function.  However, as renal function varies in many dis-
orders not primarily associated with renal insufficiency, it 
may be an oversight.  Pertinent to the current discussion 
is the fact that overestimation of  systemic inflammatory 
activity, when using plasma levels as the biomarker in the 
face of  renal insufficiency, will have a negative impact on 
the linear relationship between plasma neopterin and the 
urine neopterin:creatinine ratio.
Another factor potentially confounding the correlation is 
that neopterin may be synthesised within the renal tis-
sue.  Although no such evidence could be found for the 
healthy kidney, it is feasible to expect intra-renal neop-
terin synthesis in patients with immune-complex related 
renal diseases.  This has, in fact, been observed in patients 
with mesangial proliferative glomerulonephritis where in-
dications were found for intra-renal neopterin synthesis 
and where increased urine neopterin positively correlated 
with histopathological findings19.  Under such conditions, 
increased urine neopterin would reflect macrophage ac-
tivation and active inflammation within the kidneys19.  A 
parallel increase in plasma neopterin would be unlikely. 
Urine neopterin levels would then be a biomarker for 
monitoring the progression of  the renal disease and not 
systemic inflammation.
In addition to the impact that a decline in renal clearance 
and immune-complex related intra-renal activity may have 
on correlations between plasma/serum neopterin and the 
urine ratio,  renal tubular processes could potentially also 
have an effect.  Early indications suggested that neopterin 
is not only removed from the circulation by filtration, but 
that it may also be secreted along the renal tubuli and that 
neopterin clearance values may be 1.8 times that of  creati-
nine clearance16.  Although creatinine clearance is clinical-
ly used as a measure of  GFR, creatinine is, in fact, actively 
secreted from the peritubular capillaries into the proximal 
tubule to the extent that creatinine clearance may over-
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estimate actual GFR by 10% to 20%20.  With the urine 
concentration of  both substances partially dependent on 
tubular secretion it should be remembered that tubular 
secretion is affected by many factors.  Tubular secretion 
of  creatinine is, for instance, influenced by physical ac-
tivity, diet, time of  day and several medications20.  Any 
factor influencing the secretion of  either or both could 
thus change their ratio in urine and by implication impact 
on the linear relationship between plasma neopterin and 
the urine neopterin:creatinine ratio.  In addition to the 
above, circadian rhythms, and therefore time of  day when 
samples are collected, may also influence the relationship. 
A circadian rhythm in the urine neopterin: creatinine ratio 
has indeed been shown to exist with peak values at 02:30, 
mainly due to a dip in creatinine excretion, and again at 
06:30, following the peak in the circadian rhythm of  plas-
ma neopterin21.  These variations are said to be less no-
ticeable during day time21.  This questions the assumption 
of  first or early morning as the best time for specimen 
collection and stresses the importance for serial assess-
ments to be performed at the same time of  day.
 
Correlations and diagnostic agreement
As seen from Table 1, significant positive correlations 
were generally found between plasma neopterin and the 
urine neopterin:creatinine ratio.  However, a statistically 
significant correlation does not imply diagnostic agree-
ment.  This is borne out by results of  studies where 
plasma/serum neopterin levels and the urine neopter-
in:creatinine ratios were concurrently assessed and both 
were independently tested as biomarkers.  As illustrated 
in column 5 of  Table 1, plasma neopterin and the urine 
neopterin:creatinine ratio may differ in their diagnostic 
sensitivity and discriminatory power.
Statistical discussion of  correlation versus agree-
ment
From a purely statistical point of  view correlations do 
not equate diagnostic agreement.  In order to determine 
statistical agreement between two quantitative measures, 
one needs to check whether a y = x relationship exists 
between the measures22.  Although one would assume 
that a linear regression or Pearson’s correlation analysis 
(y = a + bx) would be able to determine agreement if  the 
intercept of  the regression line (a) equals zero and the 
slope (b) equals one, this is not the case22.  The crucial 
difference between the two types of  analyses is that a re-
gression or correlation analysis determines the difference 
between x and the average of  y (i.e. equality of  averages), 
while agreement determines the equality of  individual 
values22.  Therefore, one cannot determine quantitative 
agreement of  measures based on equality of  means and 
a high degree of  correlation.  In order to say that one 
marker agrees sufficiently and is therefore considered 
interchangeable with the other, special methods that de-
termine the agreement between individual values, such 
as limits of  disagreement or intra-class correlations, are 
required22. 
Although largely beyond the scope of  this writing, it is 
perhaps necessary to mention that increased neopterin 
concentrations have also been found in cerebrospinal flu-
id, synovial fluid, pancreatic juice, saliva, ascites fluid, cord 
blood and broncho-alveolar lavage under localised infec-
tious or inflammatory conditions. Neopterin synthesis is 
in such cases probably induced in local endothelial cells 
under the influence of  INF-γ19,23.  Neopterin concentra-
tion in these fluids may give more direct information on 
local macrophage stimulation and inflammatory activity. 
However, collection of  such fluids is, in the majority of  
cases, more invasive.
 
Conclusion
Despite the fact that several factors may potentially in-
fluence the linear relationship between plasma neop-
terin and the urine neopterin:creatinine ratio, positive 
correlations of  varying statistical significance generally 
exist between the two in individuals with normal renal 
function. This would suggest plasma neopterin and the 
neopterin:creatinine ratio in urine both to be markers of  
pro-inflammatory status and suitable for the serial moni-
toring of  disease progression or the effect of  therapeutic 
interventions. However, renal disease can, depending on 
the type of  renal disorder, confound the diagnostic and 
prognostic value of  both plasma neopterin and the urine 
neopterin:creatinine ratio.  Since correlation analysis de-
termines the equality of  means and not individual values, 
statistically significant correlations do not necessarily im-
ply diagnostic agreement.
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